We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Unum Therapeutics Inc | NASDAQ:UMRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.35 | 2.35 | 2.40 | 0 | 01:00:00 |
FORM 4
[
X
]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
FMR LLC |
2. Issuer Name
and
Ticker or Trading Symbol
Unum Therapeutics Inc. [ UMRX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner _____ Officer (give title below) __ X __ Other (specify below) See Remark 1 |
245 SUMMER STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
BOSTON, MA 02210 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 4/3/2018 | C | 349462 | A | (1) | 349462 | I | F-Prime Capital Partners Healthcare Fund IV LP | ||
Common Stock | 4/3/2018 | C | 8601 | A | (1) | 358063 | I | F-Prime Capital Partners Healthcare Fund IV LP | ||
Common Stock | 4/3/2018 | P | 94052 | A | $12 | 452115 | I | F-Prime Capital Partners Healthcare Fund IV LP | ||
Common Stock | 4/3/2018 | C | 1890701 | A | (1) | 1890701 | I | Impresa Fund III Limited Partnership | ||
Common Stock | 4/3/2018 | C | 46534 | A | (1) | 1937235 | I | Impresa Fund III Limited Partnership | ||
Common Stock | 4/3/2018 | C | 22682 | A | (1) | 22682 | I | F-Prime Capital Partners Healthcare Advisors Fund IV LP | ||
Common Stock | 4/3/2018 | C | 558 | A | (1) | 23240 | I | F-Prime Capital Partners Healthcare Advisors Fund IV LP |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Series A Preferred Stock | (1) | 4/3/2018 | C | 548702 | (1) | (1) | Common Stock | 349462 | (1) | 0 | I | F-Prime Capital Partners Healthcare Fund IV LP | |||
Series A Preferred Stock | (1) | 4/3/2018 | C | 2968650 | (1) | (1) | Common Stock | 1890701 | (1) | 0 | I | Impresa Fund III Limited Partnership | |||
Series A Preferred Stock | (1) | 4/3/2018 | C | 35614 | (1) | (1) | Common Stock | 22682 | (1) | 0 | I | F-Prime Capital Partners Healthcare Advisors Fund IV LP | |||
Series B Preferred Stock | (1) | 4/3/2018 | C | 13505 | (1) | (1) | Common Stock | 8601 | (1) | 0 | I | F-Prime Capital Partners Healthcare Fund IV LP | |||
Series B Preferred Stock | (1) | 4/3/2018 | C | 73065 | (1) | (1) | Common Stock | 46534 | (1) | 0 | I | Impresa Fund III Limited Partnership | |||
Series B Preferred Stock | (1) | 4/3/2018 | C | 877 | (1) | (1) | Common Stock | 558 | (1) | 0 | I | F-Prime Capital Partners Healthcare Advisors Fund IV LP |
Remarks:
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund IV LP is F-Prime Capital Partners Healthcare Advisors Fund IV LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the general partner of its general partner and its investment manager. Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
FMR LLC
245 SUMMER STREET BOSTON, MA 02210 |
|
|
|
See Remark 1 |
Signatures
|
||
Marc R. Bryant, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson | 4/4/2018 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Unum Therapeutics Chart |
1 Month Unum Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions